Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986506 + BNT327 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986506 | BMS986506|BMS 986506 | Limited information is currently available on BMS-986506 (Oct 2025). | ||
| BNT327 | PM8002|Pumitamig|BNT-327|BNT 327|BM-8002 | PD-L1/PD-1 antibody 138 VEGFA Antibody 6 | BNT327 (PM8002) is a bispecific antibody that targets VEGFA and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, no. 16_suppl (May 29, 2024) 5524). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07195682 | Phase I | BMS-986506 + BNT327 BMS-986506 + BNT327 + Ipilimumab BMS-986506 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Recruiting | USA | ITA | FRA | ESP | CAN | 0 |